Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Mirvetuximab Soravtansine + SL-172154|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Mirvetuximab Soravtansine||Elahere||IMGN853|M9346A-sulfo-SPDB-DM4|mirvetuximab soravtansine-gynx||FOLR1-targeted Therapy 14||Elahere (mirvetuximab soravtansine) is an antibody-drug conjugate comprised of an antibody directed against FOLR1 linked to the tubulin polymerization-inhibiting drug DM4, leading to cell death in Folr1-expressing tumors (PMID: 26136852, PMID: 25904506). Elahere (mirvetuximab soravtansine) is FDA approved for use in patients with FOLR1-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatments (FDA.gov).|
|SL-172154||SL172154|SL 172154|CD172a-Fc-CD40L Chimeric Protein SL-172154||SL-172154 is a fusion protein that is engineered to target CD47 on tumor cells and CD40 on antigen presenting cells (APCs), which inhibits CD47/SIRPa signaling and potentially results in increased anti-tumor immune response (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT05483933||Phase I||Pegylated liposomal doxorubicin + SL-172154 Mirvetuximab Soravtansine + SL-172154||Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers||Recruiting||USA||0|